Defining the putative inhibitory site for a selective negative allosteric modulator of human α4β2 neuronal nicotinic receptors

ACS Chemical Neuroscience

Volumn 3, Issue 9, 2012, Pages 682-692

  Henderson, Brandon J ^a   González Cestari, Tatiana F ^b   Yi, Bitna ^b   Pavlovicz, Ryan E ^b   Boyd, R Thomas ^b   Li, Chenglong ^b   Bergmeier, Stephen C ^c   McKay, Dennis B ^b  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO UNIVERSITY   (United States)

Author keywords

4?2; Negative allosteric modulator (NAM); neuronal nicotinic acetylcholine receptors (nAChRs); nicotine; Site directed mutagenesis; structure activity relationships

Indexed keywords

ANTHRANILIC ACID DERIVATIVE; ESTER DERIVATIVE; GLUTAMINE; KAB 18; LIGAND; MUTANT PROTEIN; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR BLOCKING AGENT; PHENYLALANINE; PIPERIDINE DERIVATIVE; THREONINE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; IN VITRO STUDY; MOLECULAR DOCKING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; TOBACCO DEPENDENCE;

BINDING SITES; BIPHENYL COMPOUNDS; CALCIUM; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; NEURONS; NICOTINIC ANTAGONISTS; PHENYLALANINE; PIPERIDINES; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP; THREONINE;

EID: 84866431399     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn300035f     Document Type: Article

References (37)

1. Lloyd, G. K. and Williams, M. (2000) Neuronal nicotinic acetylcholine receptors as novel drug targets J. Pharmacol. Exp. Ther. 292, 461-467 (Pubitemid 30067407)
2. Schuller, H. M. (2009) Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nature Rev. Cancer 9, 195-205
3. Improgo, M. R. D., Scofield, M. D., Tapper, A. R., and Gardner, P. D. (2010) The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: Dual role in nicotine addiction and lung cancer Prog. Neurobiol. 92, 212-226
4. Gotti, C., Moretti, M., Bohr, I., Ziabreva, I., Vailati, S., Longhi, R., Riganti, L., Gaimarri, A., McKeith, I. G., Perry, R. H., Aarsland, D., Larsen, J. P., Sher, E., Beattie, R., Clementi, F., and Court, J. A. (2006) Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimers disease, Parkinsons disease and dementia with Lewy bodies by immunoprecipitation Neurobiol. Dis. 23, 481-489 (Pubitemid 44097037)
5. Lukas, R. J., Changeux, J. P., Le Novere, N., Albuquerque, E. X., Balfour, D. J., Berg, D. K., Bertrand, D., Chiappinelli, V. A., Clarke, P. B., Collins, A. C., Dani, J. A., Grady, S. R., Kellar, K. J., Lindstrom, J. M., Marks, M. J., Quik, M., Taylor, P. W., and Wonnacott, S. (1999) International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits Pharmacol. Rev. 51, 397-401 (Pubitemid 29269984)
6. Jensen, A. A., Frolund, B., Lijefors, T., and Krogsgaard-Larsen, P. (2005) Neuronal nicotinic acetylcholine receptors: Structural revelations, target identifications, and therapeutic inspirations J. Med Chem. 48, 4705-4745 (Pubitemid 41038456)
7. Albuquerque, E. X., Pereira, E. F., Alkondon, M., and Rogers, S. W. (2009) Mammalian nicotinic acetylcholine receptors: from structure to function Physiol. Rev. 89, 73-120
8. Tapper, A. R., McKinney, S. L., Nashmi, R., Schwarz, J., Deshpande, P., Labarca, C., Whiteaker, P., Marks, M. J., Collins, A. C., and Lester, H. A. (2004) Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization Science 306, 1029-1032 (Pubitemid 39482905)
9. Picciotto, M. R., Zoli, M., Rimondini, R., Lena, C., Marubio, L. M., Pich, E. M., Fuxe, K., and Changeux, J. P. (1998) Acetylcholine receptors containing the beta 2 subunit are involved in the reinforcing properties of nicotine Nature 391, 173-177 (Pubitemid 28092475)
10. Rice, M. E. and Cragg, S. J. (2004) Nicotine amplifies reward-related dopamine signals in striatum Nature Neurosci. 7, 583-584 (Pubitemid 38691894)
11. Knight, C., Howard, P., Baker, C. L., and Marton, J. P. (2010) The cost-effectiveness of an extended course (12 + 12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: An extension and update to the BENESCO model Value Health 13, 209-214
12. Fiore, M. C., McCarthy, D. E., Jackson, T. C., Zehner, M. E., Jorenby, D. E., Mielke, M., Smith, S. S., Guiliani, T. A., and Baker, T. B. (2004) Integrating smoking cessation treatment into primary care: an effectiveness study Prevent. Med. 38, 412-420 (Pubitemid 38327013)
13. Mihalak, K. B., Carroll, F. I., and Luetje, C. W. (2006) Varenicline is a partial agonist at alpha 4 beta 2 and a full agonist at alpha 7 neuronal nicotinic receptors Mol. Pharmacol. 70, 801-805 (Pubitemid 44268437)
14. Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., Sands, S. B., Schaeffer, E., Schulz, D. W., Tingley, F. D., III, and Williams, K. E. (2007) Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid Neuropharmacology 52, 985-994 (Pubitemid 46227486)
15. Taly, A., Corringer, P. J., Guedin, D., Lestage, P., and Changeux, J. P. (2009) Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system Nat. Rev. Drug Discovery 8, 733-750
16. Grady, S. R., Drenan, R. M., Breining, S. R., Yohannes, D., Wageman, C. R., Fedorov, N. B., McKinney, S., Whiteaker, P., Bencherif, M., Lester, H. A., and Marks, M. J. (2010) Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2-, alpha 6 beta 2-, alpha 3 beta 4- and alpha 7-nicotine acetylcholine receptors Neuropharmacology 58, 1054-1066
17. Lopez-Hernandez, G. Y., Thinschmidt, J. S., Zheng, G. R., Zhang, Z. F., Crooks, P. A., Dwoskin, L. P., and Papke, R. L. (2009) Selective inhibition of acetylcholine-evoked responses of alpha 7 neuronal nicotinic acetylcholine receptors by novel tris- and tetrakis-azaaromatic quaternary ammonium antagonists Mol. Pharmacol. 76, 652-666
18. Yoshimura, R. F., Hogenkamp, D. J., Li, W. Y., Tran, M. B., Belluzzi, J. D., Whittemore, E. R., Leslie, F. M., and Gee, K. W. (2007) Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats J. Pharmacol. Exp. Ther. 323, 907-915 (Pubitemid 350146068)
19. Weltzin, M. M. and Schulte, M. K. (2010) Pharmacological characterization of the allosteric modulator desformylflustrabromine and its interaction with alpha4beta2 neuronal nicotinic acetylcholine receptor orthosteric ligands J. Pharmacol. Exp. Ther. 334, 917-926
20. Taylor, P., Talley, T. T., Radic, Z., Hansen, S. B., Hibbs, R. E., and Shi, J. (2007) Structure-guided drug design: conferring selectivity among neuronal nicotinic receptor and acetylcholine-binding protein subtypes Biochem. Pharmacol. 74, 1164-1171 (Pubitemid 47417937)
21. Rose, J. E., Behm, F. M., Westman, E. C., Levin, E. D., Stein, R. M., and Ripka, G. V. (1994) Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone Clin. Pharmacol. Ther. 56, 86-99 (Pubitemid 24251569)
22. Watkins, S. S., Epping-Jordan, M. P., Koob, G. F., and Markou, A. (1999) Blockade of nicotine self-administration with nicotinic antagonists in rats Pharmacol., Biochemistry., Behav. 62, 743-751 (Pubitemid 29127180)
23. Corrigall, W. A. and Coen, K. M. (1994) Nicotine self-administration and locomotor activity are not modified by the 5-HT3 antagonists ICS 205-930 and MDL 72222 Pharmacol., Biochemistry., Behav. 49, 67-71 (Pubitemid 24297258)
24. Gonzalez-Cestari, T. F., Henderson, B. J., Pavlovicz, R. E., McKay, S. B., El-Hajj, R. A., Pulipaka, A. B., Orac, C. M., Reed, D. D., Boyd, R. T., Zhu, M. X., Li, C., Bergmeier, S. C., and McKay, D. B. (2009) Effect of novel negative allosteric modulators of neuronal nicotinic receptors on cells expressing native and recombinant nicotinic receptors: implications for drug discovery J. Pharmacol. Exp. Ther. 328, 504-515
25. Henderson, B. J., Pavlovicz, R. E., Allen, J. D., Gonzalez-Cestari, T. F., Orac, C. M., Bonnell, A. B., Zhu, M. X., Boyd, R. T., Li, C., Bergmeier, S. C., and McKay, D. B. (2010) Negative allosteric modulators that target human alpha4beta2 neuronal nicotinic receptors J. Pharmacol. Exp. Ther. 334, 761-774
26. Henderson, B. J., Carper, D. J., Gonzalez-Cestari, T. F., Yi, B., Mahasenan, K., Pavlovicz, R. E., Dalefield, M. L., Coleman, R. S., Li, C., and McKay, D. B. (2011) Structure-activity relationship studies of sulfonylpiperazine analogues as novel negative allosteric modulators of human neuronal nicotinic receptors J. Med. Chem. 54, 8681-8692
27. Neubig, R. R., Spedding, M., Kenakin, T., and Christopoulos, A. (2003) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology Pharmacol. Rev. 55, 597-606 (Pubitemid 37500521)
28. Pavlovicz, R. E., Henderson, B. J., Bonnell, A. B., Boyd, R. T., McKay, D. B., and Li, C. (2011) Identification of a negative allosteric site on human alpha4beta2 and alpha3beta4 neuronal nicotinic acetylcholine receptors PloS One 6, e24949
29. Mahasenan, K. V., Pavlovicz, R. E., Henderson, B. J., Gonzalez-Cestari, T. F., Yi, B. N., McKay, D. B., and Li, C. L. (2011) Discovery of novel alpha 4 beta 2 neuronal nicotinic receptor modulators through structure-based virtual screening ACS Med. Chem. Lett. 2, 855-860
30. Henderson, B. J., Orac, C. M., Maciagiewicz, I., Bergmeier, S. C., and McKay, D. B. (2012) 3D-QSAR and 3D-QSSR models of negative allosteric modulators facilitate the design of a novel selective antagonist of human alpha4beta2 neuronal nicotinic acetylcholine receptors Bioorg. Med. Chem. Lett. 22, 1797-1813
31. Arias, H. R., McCardy, E. A., Gallagher, M. J., and Blanton, M. P. (2001) Interaction of barbiturate analogs with the Torpedo californica nicotinic acetylcholine receptor ion channel Mol. Pharmacol. 60, 497-506 (Pubitemid 32781556)
32. Jozwiak, K., Ravichandran, S., Collins, J. R., Moaddel, R., and Wainer, I. W. (2007) Interaction of noncompetitive inhibitors with the alpha 3 beta 2 nicotinic acetylcholine receptor investigated by affinity chromatography and molecular docking J. Med. Chem. 50, 6279-6283
33. Hamouda, A. K., Jin, X., Sanghvi, M., Srivastava, S., Pandhare, A., Duddempudi, P. K., Steinbach, J. H., and Blanton, M. P. (2009) Photoaffinity labeling the agonist binding domain of alpha4beta4 and alpha4beta2 neuronal nicotinic acetylcholine receptors with [(125)I]epibatidine and 5[(125)I]A-85380 Biochim. Biophys. Acta 1788, 1987-1995
34. Blum, A. P., Lester, H. A., and Dougherty, D. A. (2010) Nicotinic pharmacophore: the pyridine N of nicotine and carbonyl of acetylcholine hydrogen bond across a subunit interface to a backbone NH Proc. Natl. Acad. Sci. U.S.A. 107, 13206-13211
35. Bergmeier, S. C., Lapinsky, D. J., Free, R. B., and McKay, D. B. (1999) Ring E analogs of methyllycaconitine (MLA) as novel nicotinic antagonists Bioorg. Med. Chem. Lett. 9, 2263-2266 (Pubitemid 29371948)
36. Bergmeier, S. C., Ismail, K. A., Arason, K. M., McKay, S., Bryant, D. L., and McKay, D. B. (2004) Structure activity studies of ring E analogues of methyllycaconitine. Part 2: Synthesis of antagonists to the alpha3beta4* nicotinic acetylcholine receptors through modifications to the ester Bioorg. Med. Chem. Lett. 14, 3739-3742 (Pubitemid 38760072)
37. Huang, J., Orac, C. M., McKay, S., McKay, D. B., and Bergmeier, S. C. (2008) The synthesis of 5-substituted ring E analogs of methyllycaconitine via the Suzuki-Miyaura cross-coupling reaction Bioorg. Med. Chem. Lett. 16, 3816-3824 (Pubitemid 351484032)